Company Overview - Art Technology Acquisition Corp. is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [1] - The company may pursue acquisition opportunities in any business or industry or at any stage of its corporate evolution, with a primary focus on technology, art, financial services, and investment banking sectors [1] Trading Information - Starting February 27, 2026, holders of units sold in the initial public offering can elect to separately trade the Company's Class A ordinary shares and warrants [1] - The Class A ordinary shares and warrants will trade on the Nasdaq Global Market under the symbols "ARTC" and "ARTCW," respectively, while units not separated will continue to trade under the symbol "ARTCU" [1] Leadership - The company is led by Daniel G. Cohen, who serves as Chairman and Chief Executive Officer, and Katherine Fleming, who is the Vice Chairman [1]

Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; completed payments of outstanding debtHOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...

Core Viewpoint - Commercial Vehicle Group (CVG) is scheduled to hold its quarterly conference call on March 11, 2026, to discuss the financial results for the fourth quarter and full year of 2025 [1]. Group 1 - The conference call will take place at 8:30 a.m. ET and will be preceded by a press release and presentation [1]. - Toll-free participants can join the call by dialing (800) 549-8228 with conference code 51917, while international participants can dial (289) 819-1520 using the same code [2]. - The call will be available via webcast on CVG's website and will be archived for one year [2]. Group 2 - A telephonic replay of the conference call will be accessible until March 25, 2026, with specific numbers provided for toll-free and toll callers [3]. - The company emphasizes its commitment to delivering solutions to complex design, engineering, and manufacturing challenges, positively impacting customers and communities [4].

- Initial 2026 AFFO Guidance of $1.39 to $1.41 per diluted share -- Initial 2026 Acquisition Volume Guidance of $115 Million to $125 Million -- Subsequently Expanded Aggregate Unsecured Credit Facilities by $115 Million to $555 Million -- Subsequent $44.2 Million of Equity Sales via ATM Program - CEDARHURST, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Postal Realty Trust, Inc. (NYSE: PSTL) (the “Company”), an internally managed real estate investment trust that owns and manages over 2,200 properties leased prim ...

Core Insights - Globus Medical, Inc. reported strong financial results for Q4 and the full year of 2025, with double-digit sales and earnings growth, driven by the successful integration of recent acquisitions and a focus on innovation [4][5]. Financial Performance - Q4 2025 worldwide net sales reached $826.4 million, a 25.7% increase from Q4 2024, with U.S. net sales up 27.5% and international sales up 19.0% [4][5]. - For the full year 2025, worldwide net sales totaled $2,938.9 million, reflecting a 16.7% increase over 2024, with U.S. sales increasing by 18.4% and international sales by 10.0% [5][6]. - GAAP net income for Q4 2025 was $140.6 million, a significant increase of 430.4% year-over-year, primarily due to higher sales and contributions from the Nevro acquisition [6][7]. - Non-GAAP diluted EPS for Q4 2025 was $1.28, up 52.1% from $0.84 in Q4 2024 [7][8]. Business Segments - The U.S. Spine business grew revenue by 10% in Q4 2025 compared to the prior year, while Enabling Technologies saw a remarkable growth of 19% [4][6]. - For the full year, Musculoskeletal Solutions generated $2,797.9 million in sales, while Enabling Technologies contributed $141.0 million [31]. Guidance and Future Outlook - The company reaffirmed its 2026 revenue guidance in the range of $3.18 to $3.22 billion and updated its non-GAAP fully diluted EPS guidance to $4.40 to $4.50 [9]. - The focus for 2026 includes scaling growth, expanding the sales force, and launching a robust new product pipeline to address unmet clinical needs [4][9]. Cash and Liquidity - As of December 31, 2025, cash and cash equivalents were $526.2 million, down from $784.4 million in 2024, with total cash, cash equivalents, and marketable securities at $629.1 million [33]. - The company generated $753.4 million in net cash from operating activities for the year, a significant increase from $520.6 million in 2024 [28]. Integration and Strategic Initiatives - The successful integration of NuVasive and Nevro has been highlighted as a key driver of value creation and market penetration [4][6]. - The company aims to enhance surgical outcomes through its Globus surgical intelligence closed-loop ecosystem, which integrates patient selection, surgical techniques, and complementary implants [4].

HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the fourth quarter and twelve months ended December 31, 2025. Net income attributable to Par Pacific stockholders of $77.7 million, or $1.53 per diluted share, for the fourth quarter and $369.4 million, or $7.16 per diluted share, for the full yearAdjusted Net Income attributable to Par Pacific stockholders of $59.5 million, or $1.17 per diluted share, ...

LITTLE ROCK, Ark., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its Chief Financial Officer and Treasurer, Paul Bullington, is scheduled to present at the J.P. Morgan 2026 Global Leveraged Finance Conference. The presentation is scheduled for 3:45 PM EST on March 3, 2026 in Miami, FL. This presentation will not be webcast; however, any investor materials will be made available on Uniti’s Investor Relations website at investor.uniti.com. ABOUT UNITI Uniti ( ...

Management to Host Conference Call on Friday, February 27, 2026, at 9:00 a.m. Eastern timeBALLERUP, Denmark, Feb. 24, 2026 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (NASDAQ: LIQT), a leading clean technology company specializing in advanced filtration systems, will report fourth quarter and fiscal year 2025 for the period ended December 31, 2025, on Friday, February 27, 2026, before the market opens. The Company has scheduled a conference call that same day, Friday, February 27, 2026, at 9:00 a.m. Eas ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a provider of wellness and biosecurity solutions, today announced that it has entered into a securities purchase agreement with a series of American Ventures, LLC in a private placement that is expected to result in gross proceeds to the Company of approximately $31.3 million, before deducting placement agent fees and offering expenses. The private placement consists of the sale of, (i) approximately 31,333 sh ...

Core Insights - Slide Insurance Holdings, Inc. reported significant growth in both gross premiums written and net income for the fourth quarter and full year of 2025, indicating strong business performance and market position [3][5][12]. Fourth Quarter 2025 Highlights - Gross premiums written increased by 56.7% year-over-year to $618.5 million, up from $394.6 million in the prior-year period, driven by the acquisition of additional policies from Citizens and consistent renewal rates [6][10]. - Net income more than doubled to $170.4 million, compared to $75.1 million in the prior-year period, with diluted earnings per share at $1.23 [12][10]. - The combined ratio improved to 38.0%, down from 60.9% in the prior-year period, reflecting a decrease in catastrophe losses [2][11]. Full Year 2025 Highlights - For the full year, gross premiums written reached $1.80 billion, a 34.6% increase from $1.33 billion in the previous year [13]. - Net premiums earned grew by 36.2% to $1.08 billion, compared to $792.4 million in the prior year, driven by both organic and inorganic growth [13]. - Total revenue for the year was $1.16 billion, a 36.5% increase from $846.8 million in the prior year [13]. Losses and Expenses - Losses and loss adjustment expenses incurred, net, were $27.1 million for the fourth quarter, a significant improvement from $59.1 million in the prior-year period [9][14]. - Policy acquisition and other underwriting expenses increased to $42.3 million, compared to $29.1 million in the prior-year period, due to a higher number of policies in force [10][15]. - General and administrative expenses rose to $51.4 million from $45.7 million in the prior year, primarily due to additional staffing [11][15]. Future Outlook - The company expects to generate full-year gross written premiums in the range of $1.85 billion to $1.95 billion for 2026, driven by organic expansion and selective growth opportunities [17]. - Projected net income for 2026 is anticipated to be between $455 million and $470 million [18].